See more : Zimmer Biomet Holdings, Inc. (ZIM.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Forward Pharma A/S (FWP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Forward Pharma A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Golden Classic Group Limited (8281.HK) Income Statement Analysis – Financial Results
- Banco do Brasil S.A. (BDORY) Income Statement Analysis – Financial Results
- Innodisk Corporation (5289.TWO) Income Statement Analysis – Financial Results
- Avidbank Holdings, Inc. (AVBH) Income Statement Analysis – Financial Results
- Urteste S.A. (URT.WA) Income Statement Analysis – Financial Results
Forward Pharma A/S (FWP)
About Forward Pharma A/S
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -188.00K | 0.00 | 0.00 | 0.00 | 1.25B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -188.00K | 0.00 | 0.00 | 0.00 | 1.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 98.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 226.00K | 327.00K | 1.05M | 2.75M | 20.50M | 41.05M | 33.73M | 10.55M | 8.02M | 4.45M |
| General & Administrative | 3.65M | 3.06M | 4.23M | 9.54M | 17.11M | 14.38M | 15.85M | 9.15M | 1.01M | 928.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.65M | 3.06M | 4.23M | 9.54M | 17.11M | 14.38M | 15.85M | 9.15M | 1.01M | 928.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.87M | 3.39M | 5.28M | 12.28M | 37.60M | 55.43M | 49.58M | 19.70M | 9.03M | 5.37M |
| Cost & Expenses | 3.87M | 3.39M | 5.28M | 12.28M | 62.60M | 55.43M | 49.58M | 19.70M | 9.03M | 5.37M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 227.00K | 389.00K | 438.00K | 63.00K | 0.00 | 0.00 |
| Interest Expense | -1.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 416.00K | 75.00K | 32.00K |
| Depreciation & Amortization | 1.98M | -3.06M | 1.00K | 4.00K | 227.00K | 109.00K | 37.00K | 3.00K | 4.00K | 2.00K |
| EBITDA | -1.89M | -6.45M | -4.22M | -8.92M | 1.18B | -54.43M | -37.30M | -18.85M | -15.71M | -22.45M |
| EBITDA Ratio | 1,006.38% | 0.00% | 0.00% | 0.00% | 94.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.87M | -3.39M | -5.28M | -12.28M | 1.19B | -55.43M | -49.58M | -19.70M | -9.03M | -5.37M |
| Operating Income Ratio | 2,060.64% | 0.00% | 0.00% | 0.00% | 94.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.98M | -3.06M | 1.06M | 3.36M | -2.91M | 895.00K | 12.24M | 435.00K | -6.76M | -17.11M |
| Income Before Tax | -1.89M | -6.45M | -4.22M | -8.93M | 1.18B | -54.54M | -37.34M | -19.27M | -15.79M | -22.48M |
| Income Before Tax Ratio | 1,006.38% | 0.00% | 0.00% | 0.00% | 94.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.98M | 0.00 | 1.06M | -204.00K | 267.40M | -21.20M | -336.00K | -250.00K | -96.00K | -17.07M |
| Net Income | 90.00K | -6.45M | -4.22M | -8.72M | 917.09M | -33.34M | -37.00M | -19.02M | -15.70M | -22.48M |
| Net Income Ratio | -47.87% | 0.00% | 0.00% | 0.00% | 73.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.01 | -0.94 | -0.62 | -1.29 | 33.78 | -4.96 | -5.54 | -3.86 | -2.40 | -3.43 |
| EPS Diluted | 0.01 | -0.94 | -0.62 | -1.29 | 32.18 | -4.96 | -5.54 | -3.86 | -2.40 | -3.43 |
| Weighted Avg Shares Out | 6.98M | 6.86M | 6.79M | 6.76M | 27.15M | 6.72M | 6.68M | 4.93M | 6.54M | 6.54M |
| Weighted Avg Shares Out (Dil) | 6.98M | 6.86M | 6.79M | 6.76M | 28.50M | 6.72M | 6.68M | 4.93M | 6.54M | 6.54M |
Why is Forward Pharma Stock Plunging During Premarket Tuesday?
The stock price of Forward Pharma A/S (NASDAQ: FWP) fell by almost 20% during the premarket. Investors are responding negatively to the Technical Board of Appeal (TBA) of the European Patent Office (EPO), dismissing Forward's appeal to revoke the EP2801355 patent (355 patent) following...
FWP Stock: Over 20% Decrease Pre-Market Explanation
The stock price of Forward Pharma A/S (NASDAQ:FWP) fell by over 20% pre-market. This is why it happened.
Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing
COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) has dismissed Forward's appeal of the...
Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020
COPENHAGEN, Denmark, April 14, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2020. Our net loss for...
Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions
COPENHAGEN, Denmark, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to ongoing precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”)...
Goldman Sachs Group Upgrades Chr. Hansen Holding A/S (OTCMKTS:CHYHY) to Neutral
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) was upgraded by research analysts at Goldman Sachs Group from a “sell” rating to a “neutral” rating in a report issued on Tuesday, The Fly reports. A number of other brokerages have also issued reports...
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) Given Consensus Recommendation of “Hold” by Analysts
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) has been assigned a consensus rating of “Hold” from the eight ratings firms that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation and five have...
Denmark stocks higher at close of trade; OMX Copenhagen 20 up 0.65%
Denmark stocks higher at close of trade; OMX Copenhagen 20 up 0.65%
Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $176.50
Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned a consensus rating of “Buy” from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a...
Nuveen Asset Management LLC Has $1.79 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)
Nuveen Asset Management LLC lowered its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 31.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,105 shares of the biotechnology...
Source: https://incomestatements.info
Category: Stock Reports